(CercleFinance.com) – Novo Nordisk has entered into exclusive negotiations with BIO JAG, main shareholder of Biocorp, with a view to purchasing its entire stake in Biocorp, representing 45.3% of the share capital and 62.19% voting rights of Biocorp, at a price of 35.00 euros per share.
Certain minority shareholders, representing 19.0% of the share capital and 13.07% of the voting rights of Biocorp, have undertaken to transfer their shares to Novo Nordisk following the acquisition by Novo Nordisk of the Control Block.
The contemplated transaction would be followed by the filing by Novo Nordisk on a mandatory basis of a draft simplified takeover bid (OPA) relating to the balance of the securities issued by Biocorp in circulation and, if the legal conditions are met at resulting from the offer, a squeeze-out procedure and the delisting of Biocorp from Euronext Growth.
Eric Dessertenne, CEO of Biocorp, added: ‘This merger project rewards our efforts, which began 5 years ago, to digitize the treatment and monitoring of chronic patients, with the constant objective of making their daily lives easier. Our teams are excited to continue this public health mission, which will be intensified by the strength of Novo Nordisk’s global presence. ‘
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
